Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $1.6 million.

  • Artiva Biotherapeutics' Share-based Compensation fell 1447.3% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 1984.49%. This contributed to the annual value of $7.0 million for FY2024, which is 103.5% down from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Share-based Compensation of $1.6 million as of Q3 2025, which was down 1447.3% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Share-based Compensation ranged from a high of $2.2 million in Q4 2024 and a low of $1.4 million during Q3 2023
  • In the last 3 years, Artiva Biotherapeutics' Share-based Compensation had a median value of $1.5 million in 2025 and averaged $1.7 million.
  • Per our database at Business Quant, Artiva Biotherapeutics' Share-based Compensation soared by 5689.66% in 2024 and then tumbled by 1447.3% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Share-based Compensation stood at $1.4 million in 2023, then skyrocketed by 56.9% to $2.2 million in 2024, then decreased by 25.32% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.5 million for Q2 2025, and $2.1 million during Q1 2025.